Results 1 to 10 of about 475,202 (310)

Systemic Lupus Erythematosus with and without Anti-dsDNA Antibodies: Analysis from a Large Monocentric Cohort [PDF]

open access: yesMediators of Inflammation, 2015
Objectives. The anti-dsDNA antibodies are a marker for Systemic Lupus Erythematosus (SLE) and 70–98% of patients test positive. We evaluated the demographic, clinical, laboratory, and therapeutical features of a monocentric SLE cohort according to the ...
Conti Fabrizio   +9 more
doaj   +2 more sources

Lupus nephritis [PDF]

open access: yesNature Reviews Disease Primers, 2020
Hans-Joachim Anders   +2 more
exaly   +3 more sources

Living with systemic lupus erythematosus in 2020: a European patient survey

open access: yesLupus Science and Medicine, 2021
Objective The aim of this study was to analyse the 2020 burden of Systemic Lupus Erythematosus (SLE) in Europe, from the patients’ perspective.Methods In May 2020, Lupus Europe, the European umbrella patient association for SLE, designed and disseminated
Alain Cornet   +3 more
doaj   +1 more source

Membrane and Soluble CD137 in Systemic Lupus Erythematosus: Role as Biomarkers for Disease Activity

open access: yesJournal of Immunology Research, 2023
Objective. The role of T cells in the pathogenesis of systemic lupus erythematosus (SLE) has recently gained attention. Costimulatory molecules are membrane proteins strictly associated with T-cell receptor (TCR), acting by activating or inhibiting T ...
Fulvia Ceccarelli   +8 more
doaj   +1 more source

Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence

open access: yesLupus Science and Medicine, 2021
Background Use of hydroxychloroquine (HCQ) is common in patients with lupus erythematosus. Long-term use (ie, ≥5 years) and high-dose HCQ (ie, >5 mg/kg/day) are both risk factors for developing HCQ retinopathy.
Ronald F van Vollenhoven   +7 more
doaj   +1 more source

Patients with systemic lupus erythematosus and their experience with vaccination against COVID-19: a descriptive and explanatory study

open access: yesReumatismo, 2022
Not ...
F. Ceccarelli   +5 more
doaj   +1 more source

Development of Systemic Autoimmune Diseases in Healthy Subjects Persistently Positive for Antiphospholipid Antibodies: Long-Term Follow-Up Study

open access: yesBiomolecules, 2022
We longitudinally followed a single-center cohort of anti-phospholipid (aPL) positive healthy subjects to evaluate the evolution to systemic autoimmune diseases (sAD) and to describe clinical and serological associated features.
Fulvia Ceccarelli   +10 more
doaj   +1 more source

A Toll for lupus [PDF]

open access: yes, 2005
Toll-like receptor (TLR)-9 recognizes CpG motifs in microbial DNA. TLR9 signalling stimulates innate antimicrobial immunity and modulates adaptive immune responses including autoimmunity against chromatin, e.g., in systemic lupus erythematosus (SLE ...
Anders HJ, H-J Anders, Stacey KJ
core   +1 more source

Lupus erythematodes

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2023
ZusammenfassungDer kutane Lupus erythematodes manifestiert sich mit oder ohne systemische Beteiligung mit einem breiten klinischen Spektrum. Die Pathogenese der Erkrankung ist durch einen Toleranzverlust gegenüber körpereigenen Antigenen und einer chronisch schubweisen Aktivierung des angeborenen und adaptiven Immunsystems geprägt.
Claudia, Günther, Jörg, Wenzel
openaire   +2 more sources

KITD816V+ systemic mastocytosis associated with KITD816V+ acute erythroid leukaemia: first case report with molecular evidence for same progenitor cell derivation [PDF]

open access: yes, 2009
Toll-like receptor (TLR)-9 recognizes CpG motifs in microbial DNA. TLR9 signalling stimulates innate antimicrobial immunity and modulates adaptive immune responses including autoimmunity against chromatin, e.g., in systemic lupus erythematosus (SLE ...
H-P Horny   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy